CSL pushes pricing limits with first hemophilia B gene therapy approval

The limits of gene therapy pricing are once again being pushed this year with the approval of Hemgenix from CSL at a $3.5 million list price, which comes with no details about value-based agreement terms that may be offered.

CSL Ltd. (ASX:CSL) will charge $3.5 million for the single-administration gene therapy, according to a statement provided to BioCentury after FDA approved Hemgenix etranacogene dezaparvovec to treat hemophilia B. ...